David Longo

Biography
David Longo is the Founder and Chief Executive Officer (CEO) of Ordaōs. As CEO of Ordaōs, Longo leads a strong scientific team to design novel mini-proteins that help drug hunters deliver safer and more effective treatments. Longo brings to Ordaōs, broad experience in innovation and technology, that compel him to approach protein design in a unique way. His expertise in AI and machine learning is incorporated into Ordaōs Design Engine, driving the rapid creation of never-before-seen mini-proteins with improved probability of more therapeutically effective candidates. Prior to Ordaōs, this entrepreneur led a series of companies which he grew into successful entities. Longo has a Master's in Biotechnology from Harvard University, graduate certificates in AI, Machine Learning, Innovation and Technology from Stanford University and Massachusetts Institute of Technology (MIT), and a masters Certificate in Music Production from Berklee College of Music.

---

Talk
Adversarial Harmony: The Skeptical Symphony of Biologics Design
This talk explores the Ordaos Design Engine's "skeptical symphony." By orchestrating hundreds of adversarial AI models grounded in diverse physical principles, we ruthlessly challenge every design assumption. This rigorous internal conflict forces consensus across varied datasets, ensuring generalizability and delivering robust, developable biologics that survive the skepticism of nature.

AI for Emerging Therapeutics Showcase:
Ordaos
Ordaos Bio is a techbio company that reimagines drug discovery as drug design by using a proprietary lab-in-the-loop generative AI engine to design novel mini-proteins and single-domain antibodies from scratch. Integrating diverse adversarial AI models with an ultra-rapid 5-day wet-lab validation cycle, the company engineers "true de novo" therapeutics that are optimized for function and developability against challenging, high-value targets.